Premium
SSRIs in the medical subspecialty clinic: Part two
Author(s) -
Price Lawrence H.
Publication year - 2018
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30372
Subject(s) - disappointment , subspecialty , sertraline , medicine , placebo , psychiatry , kidney disease , alternative medicine , antidepressant , psychotherapist , anxiety , psychology , pathology
Back in the March 2018 issue, I wrote a commentary titled “Why Don't SSRIs Work in the Medical Subspecialty Clinic?” The stimulus for this was our coverage that month of the results of the Chronic Kidney Disease Antidepressant Sertraline Trial, which found that sertraline was no better than placebo for depressive symptoms in patients with chronic kidney disease and major depression. I described the findings as “disappointing,” and although I intended to convey that disappointment in the title of the commentary, perhaps I erred a bit on the nihilistic side. Happily, a paper we are covering this month allows me to offer a corrective.